Enhertu Granted Breakthrough Therapy Designation in the US for Patients with HER2-Low Metastatic Breast Cancer

AstraZeneca and Daiichi Sankyo’s ENHERTU® has been granted Breakthrough Therapy Designation in the US for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received a prior systemic therapy.